EGFR and head and neck cancer: Currently indicated systemic therapies in head and neck cancer include the cytotoxic chemotherapies cisplatin, docetaxel, the anti-metabolite fluorouracil (5-FU); the anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) cetuximab; and the anti-programmed death receptor-1 (PD-1) mAbs pembrolizumab and nivolumab.